Biotechnology
-
Biogen Tops Q1 Estimates with Alzheimer's Boost
Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the...
-
Contineum Therapeutics Raises $110 Million in Successful IPO
Contineum Therapeutics' IPO success reflects investor confidence in their innovative therapies for neuroscience, inflammation, and immunology.
-
Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B
J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the...
-
Carl Icahn Ends Second Proxy Fight with Illumina (ILMN) Board
Activist investor Carl Icahn spares Illumina a second proxy contest, but continues lawsuit, leaving retail investors curious about board dynamics...
-
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
-
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
-
Biopharmaceutical M&A Surge Revitalizes Industry
Uncover the latest M&A trends in biopharma, featuring big moves by BMY, MRK, BSX, and JNJ in a market ripe with opportunity.
-
Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits
Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare...
-
AbbVie Stock in Focus with Strategic Cerevel Acquisition
AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.
-
Gilead Sciences Marks Two Years of Robust Growth
Gilead Sciences reports robust Q3 growth, driven by oncology and HIV treatments, highlighting a solid pipeline and strategic expansion in global...
-
Exact Sciences Records Stellar Q3 2023 Results
Exact Sciences showcases robust Q3 results, marking a turning point with increased revenue, diversified streams, and an upward trajectory.
-
EXACT Sciences Gears Up for Earnings Reveal
EXACT Sciences eyes a pivotal moment with its upcoming Q3 earnings report. The firm excels in ESG ratings and revenue, but operational costs raise...
-
Who is Vivek Ramaswamy and What is His Net Worth?
Vivek Ramaswamy is a new force in US politics, having risen to second place in the race for the Republican nomination. But who is Vivek Ramaswamy...
-
Are Biotech Penny Stocks Worth Investing In?
What can biotech penny stocks do for you? While investors might be attracted by the potential for outsize returns, there are serious risks to...
-
Understanding Drug Development and Approval Process
New drugs and treatments have to undergo a long process of development, clinical trials and FDA approvals before they can start bringing in revenue...
-
An Introduction to Biopharma: A New Era in Medicine
Discover the cutting-edge world of biopharmaceuticals and how it's reshaping healthcare. From advanced therapies to life-changing drugs, explore...
